Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asia Deal Watch: Daiichi Sankyo Licenses Glycotope's Gatipotuzumab ADC

Executive Summary

Daiichi Sankyo gains worldwide rights to an antibody-drug conjugate version of Glycotope’s gatipotuzumab for various cancers. Also, Tasly buys China rights to Mesoblast's CV candidates and India's Cipla grows in Africa.

Advertisement

Related Content

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera
Venture Funding Deals: I-Mab Is The Mega-Round Leader With $220m Series C
Deal Watch: Allergan, Celgene, AstraZeneca Among Biopharmas Advancing Existing Partnerships
Finance Watch: Early-Stage Firms Gain Deal-Making Insight As Golumbeski Joins VC Ranks
Genexine Seals I-O Licensing Deal With I-Mab, Builds Momentum
China Investment Roundup: Spotlight On Oncology
Interview: Fledgling ABL Bio And Its Global Ambitions In Bispecific Antibodies
Cipla Cuts Down In-House Biosimilars Plans
Daiichi Sankyo Lays Out Priorities As It Pursues Oncology Ambitions

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel